Diabetes medications and risk of Parkinson’s disease: a cohort study of patients with diabetes
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Diabetes medications and risk of Parkinson’s disease: a cohort study of patients with diabetes
Authors
Keywords
-
Journal
BRAIN
Volume -, Issue -, Pages -
Publisher
Oxford University Press (OUP)
Online
2020-07-18
DOI
10.1093/brain/awaa262
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- GLP-1’s role in neuroprotection: a systematic review
- (2019) Damla Erbil et al. BRAIN INJURY
- Body mass index, diabetes, and the risk of Parkinson's disease
- (2019) Su‐Min Jeong et al. MOVEMENT DISORDERS
- Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson’s disease
- (2018) Seung Pil Yun et al. NATURE MEDICINE
- Association between diabetes and subsequent Parkinson disease
- (2018) Eduardo De Pablo-Fernandez et al. NEUROLOGY
- Brain atrophy in middle-aged subjects with Type 2 diabetes mellitus, with and without microvascular complications
- (2018) Fang Fang et al. Journal of Diabetes
- Impact of small vessel disease on severity of motor and cognitive impairment in Parkinson’s disease
- (2018) Raymond S. Schwartz et al. JOURNAL OF CLINICAL NEUROSCIENCE
- Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial
- (2017) Dilan Athauda et al. LANCET
- Glitazone use associated with reduced risk of Parkinson's disease
- (2017) Brage Brakedal et al. MOVEMENT DISORDERS
- Propensity score analysis with partially observed covariates: How should multiple imputation be used?
- (2017) Clémence Leyrat et al. STATISTICAL METHODS IN MEDICAL RESEARCH
- Reduced incidence of Parkinson's disease after dipeptidyl peptidase-4 inhibitors-A nationwide case-control study
- (2016) Per Svenningsson et al. MOVEMENT DISORDERS
- Insulin resistance and Parkinson’s disease: A new target for disease modification?
- (2016) D. Athauda et al. PROGRESS IN NEUROBIOLOGY
- Thiazolidinediones and Parkinson Disease: A Cohort Study
- (2015) John G. Connolly et al. AMERICAN JOURNAL OF EPIDEMIOLOGY
- Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial
- (2015) LANCET NEUROLOGY
- Motor and Cognitive Advantages Persist 12 Months After Exenatide Exposure in Parkinson’s Disease
- (2015) Iciar Aviles-Olmos et al. Journal of Parkinsons Disease
- Glitazone Treatment and Incidence of Parkinson’s Disease among People with Diabetes: A Retrospective Cohort Study
- (2015) Ruth Brauer et al. PLOS MEDICINE
- Exenatide and the treatment of patients with Parkinson’s disease
- (2013) Iciar Aviles-Olmos et al. JOURNAL OF CLINICAL INVESTIGATION
- Potential Role of Glucagon-Like Peptide-1 (GLP-1) in Neuroprotection
- (2012) Christian Hölscher CNS DRUGS
- Identifying periods of acceptable computer usage in primary care research databases
- (2012) Laura Horsfall et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Diabetes and Risk of Parkinson's Disease: A systematic review and meta-analysis
- (2011) E. Cereda et al. DIABETES CARE
- An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies
- (2011) Peter C. Austin MULTIVARIATE BEHAVIORAL RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now